News

CMS is considering coverage for transcatheter aortic valve replacement (TAVR) in patients with aortic regurgitation. This would represent a significant expansion beyond the current approved indication of aortic stenosis.

Digest: CMS coverage for TAVR in aortic regurgitation would open a new market segment and provide reimbursement for an off-label use that has shown feasibility in selected patients but lacks robust trial data.

Mount Sinai researchers received a $3.6 million, four-year NIH grant to develop EVOLVE-MR, a project linking randomized trial data with Medicare records to extend mitral valve surgery evidence to real-world populations. The study will use machine learning and causal inference methods to determine whether clinical trial benefits persist in broader, more diverse patient groups over longer follow-up periods.

Digest: This research addresses the critical gap between clinical trial populations and real-world mitral regurgitation patients, potentially enabling more individualized surgical decision-making for the 13 million U.S. adults with valvular heart disease.

Medical societies and aging advocacy groups have issued initial responses to new CMS coverage policies affecting transcatheter aortic valve replacement. The policy changes appear to modify reimbursement or coverage criteria for TAVR procedures.

Digest: CMS coverage determinations directly impact TAVR access, reimbursement dynamics, and patient selection strategies for structural heart programs nationwide.

CMS finalized a national coverage determination expanding Medicare coverage for transcatheter aortic valve replacement to include asymptomatic patients with severe aortic stenosis. This represents a significant broadening of the Medicare eligible patient population beyond the previous requirement for symptomatic disease.

Digest: This reimbursement expansion substantially increases the addressable market for TAVR and aligns Medicare coverage with current clinical practice patterns and recent trial evidence in asymptomatic severe AS patients.

Banner Health is partnering with physicians to expand cardiovascular procedures in ambulatory surgery centers. The initiative aims to shift appropriate heart procedures from hospital-based settings to lower-cost ASC environments.

Digest: ASC migration of structural heart procedures could impact reimbursement models and site-of-service strategies as health systems seek cost reduction while maintaining quality outcomes.

Economic analysis suggests early transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis may be cost-effective compared to watchful waiting. The cost savings would accrue from preventing heart failure hospitalizations and complications associated with delayed intervention.

Digest: This health economics data could influence coverage decisions and clinical practice patterns by supporting intervention before symptom onset in severe AS patients.

The U.S. Department of Justice charged 455 defendants, including 90 physicians and licensed healthcare professionals, with over $6.5 billion in alleged Medicare and Medicaid fraud in a 2026 national enforcement sweep. Healthcare law experts emphasize the need to distinguish between intentional fraud and honest billing mistakes resulting from complex regulatory requirements, as federal investigations continue with CMS deferring over $1 billion in Medicaid payments pending documentation review.

Digest: Heightened federal fraud enforcement and compliance scrutiny may impact structural heart practices through increased billing audits, reimbursement delays, and pressure to document medical necessity for high-cost procedures like TAVR and mitral interventions.

Medical societies are publicly responding to a CMS proposal regarding TAVR coverage as the agency approaches its final decision. The societies' positions indicate stakeholder engagement on potential changes to reimbursement or coverage criteria for transcatheter aortic valve replacement.

Digest: CMS coverage decisions directly impact patient access to TAVR and procedural volumes at structural heart programs, particularly if eligibility criteria or site-of-service requirements change.

CMS proposed significant policy changes affecting TAVR reimbursement and coverage, prompting responses from interventional cardiologists and cardiac surgeons. The clinical and financial implications of these proposed modifications are being evaluated by the structural heart community.

Digest: CMS reimbursement policy directly impacts TAVR program sustainability, patient access, and the economic viability of structural heart programs nationwide.

CMS has proposed expanding Medicare coverage for transcatheter aortic valve replacement (TAVR) to include asymptomatic patients with severe aortic stenosis. This represents a significant policy shift from current coverage criteria that require symptomatic presentation.

Digest: Expansion of Medicare coverage to asymptomatic severe AS patients could substantially increase the eligible TAVR population and accelerate treatment timing, potentially preventing symptom development and improving outcomes.

An advocacy group is calling on the Trump administration to change regulations or policies affecting transcatheter aortic valve replacement (TAVR) access, framing the issue as government interference in clinical decision-making. No specific policy changes, clinical data, or patient access barriers are detailed in the available content.

Digest: Potential regulatory or reimbursement policy changes could significantly impact TAVR utilization patterns and patient access, though the specific issues being advocated remain unclear from this brief report.